Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. (ZTEK) generates news across several advanced technology domains, reflecting its role as an intellectual property development and commercialization company. Its disclosures highlight activity in graphene-based coatings, critical mineral development, aptamer-based healthcare technologies and fire-retardant materials, giving investors and observers multiple streams of company-specific updates.
A major news theme is Zentek’s work through its wholly owned subsidiary Albany Graphite Corp. on the Albany Graphite Project in Ontario. Recent releases describe ultra-high purity Albany graphite reaching five-nines carbon purity with an Equivalent Boron Concentration below thresholds generally referenced for nuclear applications, as well as additional nuclear suitability testing and independent verification using near-net-shaped graphite bricks. Separate announcements cover lithium-ion battery suitability testing, where spheroidized Albany graphite has shown near-theoretical anode performance under industry-standard conditions.
Another recurring topic is Zentek’s ZenGUARD™ platform for surgical masks and HVAC air filters, including corporate updates on testing under the Government of Canada’s Innovative Solutions Canada program and efforts to advance ZenGUARD™ Enhanced Air Filters in Canada and international markets. News items also address the company’s development of a Graphite Gel-Based Fire-Retardant product and an exclusive licensing arrangement with Altek Advanced Materials Inc. for commercialization in the United States.
Healthcare-focused news includes progress on multivalent aptamer countermeasures against influenza through Triera Biosciences and McMaster University, supported by a federal testing contract. Corporate governance and capital markets developments, such as CEO transitions, board appointments, annual meeting voting results and tax reassessment matters, are reported through regular press releases and associated Form 6-K filings. Readers following ZTEK news can expect updates on technology milestones, regulatory and testing programs, strategic partnerships and key corporate decisions.
Zentek Ltd. (NASDAQ: ZTEK), a Canadian intellectual property development firm, has announced the successful completion of Phase 1 testing for its ZenGUARD™-coated HVAC filters. Following this, the company will advance to Phase 2 testing under its Innovation Solutions Canada contract. Phase 1 confirmed the coating's effectiveness in reducing airborne organisms while maintaining airflow. The upcoming Phase 2 aims to further validate the coating's safety and efficacy in a classroom setting. This progression is significant for indoor air quality initiatives and commercialization efforts.
Zentek Ltd. (NASDAQ: ZTEK) has partnered with FTI Consulting to aid its U.S. market expansion, focusing on the regulatory approval process for its ZenGUARD™ nanotechnology. This partnership aims to navigate the complicated federal regulations and potentially launch ZenGUARD™, which boasts 99% antimicrobial activity, including against COVID-19. This announcement follows Zentek's recent debut on the NASDAQ, enhancing its strategy to commercialize innovative healthcare solutions.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN) has filed a provisional patent for a Graphene Oxide-Metal-Organic Framework (GO-MOF) aimed at enhancing fire retardant products. The company emphasizes environmentally friendly components and efficient production methods. Initial tests for the GO-MOF in fire retardants have shown promising results, indicating its potential application in various coatings and in creating lightweight, fire-resistant plastics for electric vehicles. Zentek's innovative approach enhances its value proposition in health and safety.
Zentek Ltd. (Nasdaq:ZTEK) announced the publication of its international patent application for ZenGUARD technology by the World Intellectual Property Office. This milestone reflects the company’s progress from scientific breakthrough to commercialization. The ZenGUARD technology, which exhibits 99% antimicrobial activity, including effectiveness against COVID-19, aims to enhance revenue potential through commercial opportunities. Zentek is scaling production in its Guelph facility and actively pursuing market opportunities for ZenGUARD, particularly in transmission prevention with coated masks.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN; OTC PINK:ZENYF) announced its SEC Form 40-F registration statement is effective, and its common stock will start trading on the Nasdaq Capital Market under the symbol ZTEK on March 22, 2022. CEO Greg Fenton stated this milestone will enhance liquidity, attract U.S. investors, and increase visibility. Zentek focuses on next-gen healthcare solutions, including ZenGUARD™, an antimicrobial coating with 99% efficacy against COVID-19, and an exclusive partnership for rapid pathogen detection technology.